Scientists have discovered the first drug of its kind that appears to slow the pace of mental decline in Alzheimer’s patients.
Solanezumab, developed by the American pharmaceutical company Eli Lilly, was shown to block memory loss in patients with a mild version of the disease, making it the first medicine ever to slow pace of damage to patients’ brains.
Existing drugs, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function, but Solanezumab attacks the deformed proteins that build up in the brain during Alzheimer’s.
Dr Doug Brown, head of research at the Alzheimer’s Society, said: “Today’s findings strongly suggest that targeting people in the earliest stages of Alzheimer’s disease with these antibody treatments is the best way to slow or stop Alzheimer’s disease. These drugs are able to reduce the sticky plaques of amyloid that build up in the brain, and now we have seen the first hints that doing this early enough may slow disease progression.”
Should further trial results be positive, it could still be up to several years before the drug would become available on the NHS. Another phase-three trial is due to report in 2016 and then the drug would need to go through regulatory approval and would need to be shown to be sufficiently beneficial to patients.
Image credit: Ann Gordon
A study carried out by researchers at Brown University has indicated that niclosamide, a drug used to treat tapeworm, and the closely related oxycloxanide, a veterinary parasite drug, could be used to successfully treat strains of the superbug MRSA.
During the study the drugs suppressed the growth of MRSA cultures in laboratory dishes and preserved the life of nematode worms infected with the bacteria. Ninety percent of MRSA-infected worms survived and large zones of growth inhibition in MRSA culture covering the petri dish plate was cleared. Both were also found to be as effective at lower concentrations as vancomycin, the drug currently used as a last resort treatment against the superbug.
Oxyclozanide was discovered to be the more effective of the two in killing the MRSA bacteria. Niclosamide, on the other hand, successfully curbed MRSA growth however it did not completely eradicate it. Moving forward experiments on rodents are now being planned.
Potential issues have been highlighted concerning the rapid way nicolsamide is cleared from the body and the poor job it performs in working its way out of the bloodstream and into tissues. However, it has been suggested that this rapid clearance may not reduce performance and could in fact be an advantage as the toxicity of the drug may be reduced.
With noclosamide already FDA approved and featured on the World Health Organization’s list of essential medicines, there are strong motivations for investigating its use as a boost to the immune system in those that have essay writing uk contracted MRSA. The less toxic oxycozanide could present an even more promising treatment should it be approved for human consumption. As oxycozanide targets the cell membrane rather than metabolic pathways, it could help prevent MRSA developing resistance to the drug.
Image credit: FWC Fish & Wildlife Research Institute
Scientists have created the first new antibiotic in 30 years – and say it could be the key to beating superbug resistance.
The new antibiotic is extracted from soil bacteria and can kill a huge range of disease-causing microbes, with scientists claiming it appears to be as good, or even better, than many existing drugs with the potential to work against a broad range of fatal infections such as pneumonia and tuberculosis.
Laboratory tests have shown the new antibiotic, teixobactin, can kill some bacteria as quickly as established antibiotics and can cure laboratory mice suffering from bacterial infections with no toxic side-effects.
Studies have also revealed the prototype drug works against harmful bacteria in a unique way that is highly unlikely to lead to drug-resistance – one of the biggest stumbling blocks in developing new antibiotics.
With fears that the world is running out of effective antibiotics given the rapid rise of drug-resistant strains of superbugs, this development could represent a huge boost for medicine. Clinical trials could begin in two years.
Image credit: marlo